2026 Comparison,EUR 135.0 million in revenue

The PolyPeptide Group revenue has demonstrated a consistent upward trajectory, reflecting the company's strategic growth and its significant position in the peptide and oligonucleotide manufacturing sector. As a leading Contract Development and Manufacturing Organization (CDMO), PolyPeptide plays a crucial role in bringing innovative therapeutics to market, a factor that directly influences its revenue streams.

Financial Highlights and Growth Trends

In the financial year 2025, PolyPeptide reported a robust performance, with its revenue reaching approximately EUR 389 million. This figure represents a notable increase of around 15.6% compared to the previous year. Further analysis of the financial reports indicates that at constant currency rates, this growth was even more pronounced, standing at approximately 16.0%. This strong revenue growth is a testament to the company's operational efficiency and market demand for its specialized services.

Looking back, the PolyPeptide Group's revenue for fiscal years ending December 2021 to 2025 has averaged around 309.5 million. The company's latest twelve months revenue has been reported at 362.3 million. For FY2024, the PolyPeptide Group revenue stood at EUR 336.8 million, marking a 5.1% increase from the prior year. This consistent growth signifies a healthy business model and expanding market share.

The annual revenue for FY has shown a positive trend, with figures like $391.87M reported for a recent fiscal year, indicating a revenue growth of 15.70% compared to the prior year. Furthermore, the PolyPeptide Group's estimated annual revenue is currently $312.6M per year, with some reports indicating an annual revenue is estimated to be $13M as of March 2026, which may refer to a specific segment or be an outlier. However, the prevailing trend points to substantial revenue generation.

Key Revenue Drivers and Market Position

The strong financial performance of PolyPeptide is significantly driven by the increasing demand for peptide and oligonucleotide-based active pharmaceutical ingredients. The company's focus on metabolic therapeutics has been a particular catalyst for growth. In the first half of 2025 (H1 2025), PolyPeptide generated EUR 167.1 million in revenue, a substantial increase of 23.7% compared to H1 2024. This growth in H1 2025 was primarily fueled by the burgeoning market for metabolic therapeutics.

PolyPeptide's strategic position as a CDMO offering services from pre-clinical through to commercial stages allows it to capture value across the entire drug development lifecycle. The company's broad portfolio of products and services caters to the fast-growing market for innovative treatments. This comprehensive offering is a key factor in its ability to secure long-term contracts and drive consistent revenue.

Financial Outlook and Strategic Goals

Looking ahead, PolyPeptide has set ambitious targets. The company aims to double revenue reported for 2023 by 2028, indicating a strong commitment to sustained growth. This mid-term outlook is supported by the company's ongoing investments in capacity expansion and technological advancements within its manufacturing facilities, including its operations in San Diego.

The PolyPeptide Group AG's financial health is also reflected in its profitability metrics. For instance, in 2025, while revenue grew 16% at constant currency, EBITDA rose by an impressive 84% to EUR 46.8 million. This marked improvement in profitability, alongside strong revenue growth, highlights the company's ability to translate market opportunities into financial success.

Investor Relations and Company Information

For stakeholders interested in the financial performance of PolyPeptide Group, resources such as the PolyPeptide Annual Report and PolyPeptide Investor Relations provide detailed insights. The availability of PolyPeptide Annual Report 2024 and PolyPeptide Annual Report 2023 offers a historical perspective on the company's financial evolution. Information regarding the PolyPeptide Group stock and its financial calendar can also be accessed through official channels. The company’s Board of Directors oversees its strategic direction, influencing its financial outcomes.

In summary, the PolyPeptide Group revenue is a key indicator of its success in the highly specialized pharmaceutical manufacturing sector. Driven by strong market demand for peptides and oligonucleotides, particularly in metabolic therapeutics, and supported by strategic investments and a comprehensive service offering, PolyPeptide is well-positioned for continued financial growth. The company's commitment to transparency, as evidenced by its detailed financial reporting and investor communications, further solidifies its reputation as a reliable and growing entity in the industry.